Trial Profile
A Phase II Study of Erlotinib (Tarceva) in Combination with Bexarotene (Targretin) in Chemorefractory Patients with Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BATTLE
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 11 Aug 2017 Planned End Date changed from 1 Nov 2015 to 1 Nov 2019.